Physiology Department, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.
Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.
Int J Mol Sci. 2021 Jan 28;22(3):1269. doi: 10.3390/ijms22031269.
Osteoarthritis (OA) is a degenerative joint disease that affects a lot of people worldwide. Current treatment for OA mainly focuses on halting or slowing down the disease progress and to improve the patient's quality of life and functionality. Autologous chondrocyte implantation (ACI) is a new treatment modality with the potential to promote regeneration of worn cartilage. Traditionally, foetal bovine serum (FBS) is used to expand the chondrocytes. However, the use of FBS is not ideal for the expansion of cells mean for clinical applications as it possesses the risk of animal pathogen transmission and animal protein transfer to host. Human platelet lysate (HPL) appears to be a suitable alternative to FBS as it is rich in biological factors that enhance cell proliferation. Thus far, HPL has been found to be superior in promoting chondrocyte proliferation compared to FBS. However, both HPL and FBS cannot prevent chondrocyte dedifferentiation. Discrepant results have been reported for the maintenance of chondrocyte redifferentiation potential by HPL. These differences are likely due to the diversity in the HPL preparation methods. In the future, more studies on HPL need to be performed to develop a standardized technique which is capable of producing HPL that can maintain the chondrocyte redifferentiation potential reproducibly. This review discusses the in vitro expansion of chondrocytes with FBS and HPL, focusing on its capability to promote the proliferation and maintain the chondrogenic characteristics of chondrocytes.
骨关节炎（OA）是一种退行性关节疾病，影响着全世界许多人。目前 OA 的治疗主要集中在阻止或减缓疾病进展，提高患者的生活质量和功能。自体软骨细胞移植（ACI）是一种新的治疗方法，具有促进磨损软骨再生的潜力。传统上，使用胎牛血清（FBS）来扩增软骨细胞。然而，由于存在动物病原体传播和动物蛋白转移到宿主的风险，FBS 并不适合用于临床应用的细胞扩增。人血小板裂解液（HPL）似乎是 FBS 的理想替代品，因为它富含生物因子，可以促进细胞增殖。迄今为止，已经发现 HPL 在促进软骨细胞增殖方面优于 FBS。然而，HPL 和 FBS 都不能防止软骨细胞去分化。HPL 对维持软骨细胞再分化潜能的作用存在不一致的结果。这些差异可能是由于 HPL 制备方法的多样性所致。未来需要更多关于 HPL 的研究，以开发一种标准化技术，能够生产出可重复性地维持软骨细胞再分化潜能的 HPL。本文综述了 FBS 和 HPL 体外扩增软骨细胞的研究进展，重点讨论了它们促进软骨细胞增殖和维持软骨细胞软骨形成特性的能力。
